Drug Trial Radar · NCT06710899
Vitamin C and Hiprex in rUTI
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Aug 2027
Study completion Jan 2028
Sponsor
- Lead sponsor
- University Hospitals of North Midlands NHS TrustAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 29, 2024
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A single centre proof of concept study to assess whether Vitamin C improves the efficacy of Methenamine Hippurate (Hiprex®) in the prophylaxis of recurrent urinary tract infections (rUTIs) in women
Conditions
- Urinary Tract Infections
Interventions
Methenamine Hippurate 1g BDDrug
Methenamine Hippurate 1g BD for 6 months
Methenamine Hippurate 1g BD + Vitamin C 1g BDDrug
Methenamine Hippurate 1g BD + Vitamin C 1g BD for 6 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of UTIsTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospitals of North Midlands NHS Trust
Stoke-on-Trent, Staffordshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.